Handa P, Kowdley KV

Idioma: Ingles.
Referencias bibliográficas: 9
Paginas: 847-848
Archivo PDF: 61.26 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 2012; 33: 522-30. doi: 10.1016/j.tips.2012.06.007. Epub 2012 Jul 12. Review.

2. Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012; 143: 307-20. doi: 10.1053/j.gastro.2012.06.004. Epub 2012 Jun 13. Review.

3. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6. Review.

4. Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, Akira S, et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A 2010; 107: 844-9. doi: 10.1073/pnas.0909781107. Epub 2009 Dec 18.

5. Herrero-Martín G1, Høyer-Hansen M, García-García C, Fumarola C, Farkas T, López-Rivas A, Jäättelä M. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J 2009 18; 28: 677-85. doi: 10.1038/emboj.2009.8. Epub 2009 Feb 5.

6. Russo GL, Russo M, Ungaro P. AMP-activated protein kinase: a target for old drugs against diabetes and cancer. Biochem Pharmacol 2013; 86: 339-50. doi: 10.1016/ j.bcp.2013.05.023. Epub 2013 Jun 6. Review.

7. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15. Review.

8. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 2010; 468: 1100-4. doi: 10.1038/nature09584.

9. Inokuchi-Shimizu S, Park EJ, Roh YS, Yang L, Zhang B, Song J, Liang S, et al. TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. J Clin Invest 2014; 124: 3566-78.